期刊
ONCOTARGET
卷 7, 期 27, 页码 42071-42085出版社
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.9817
关键词
metabolomics; citrate; spermine; HR-MAS; MRSI
资金
- Central Norway Regional Health Authority (RHA)
- RHA
- Norwegian University of Science and Technology (NTNU)
- Norwegian Cancer Society
- Nanne and Karin Gullord's foundation at the structural engineering company Alfr. Andersen Mek. Verksted & Stoberi A/S in Larvik. Norway
TMPRSS2-ERG has been proposed to be a prognostic marker for prostate cancer. The aim of this study was to identify changes in metabolism, genes and biochemical recurrence related to TMPRSS2-ERG by using an integrated approach, combining metabolomics, transcriptomics, histopathology and clinical data in a cohort of 129 human prostate samples (41 patients). Metabolic analyses revealed lower concentrations of citrate and spermine comparing ERG(high) to ERG(low) samples, suggesting an increased cancer aggressiveness of ERG(high) compared to ERG(low). These results could be validated in a separate cohort, consisting of 40 samples (40 patients), and magnetic resonance spectroscopy imaging (MRSI) indicated an in vivo translational potential. Alterations of gene expression levels associated with key enzymes in the metabolism of citrate and polyamines were in consistence with the metabolic results. Furthermore, the metabolic alterations between ERG(high) and ERG(low) were more pronounced in low Gleason samples than in high Gleason samples, suggesting it as a potential tool for risk stratification. However, no significant difference in biochemical recurrence was detected, although a trend towards significance was detected for low Gleason samples. Using an integrated approach, this study suggests TMPRSS2-ERG as a potential risk stratification tool for inclusion of active surveillance patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据